Search Results
Sole Financial Advisor to CalciMedica Inc.
Oppenheimer & Co. Inc. Acted as Sole Financial Advisor to CalciMedica Inc. on its Merger with Graybug Vision, Inc.
Sole Dealer Manager to AlTi Global, Inc. ("AlTi")
Oppenheimer & Co. Inc. acted as Sole Dealer Manager to AlTi Global, Inc. ("AlTi") on its public warrant exchange of 19.9 million warrants
Sole Bookrunner for WisdomTree
Oppenheimer & Co. Inc. acted as Exclusive Financial Advisor to Mavik Capital Management, LP on its new Senior Secured Amortizing Credit Facility from Oak Street Funding LLC.
Robust Specialty Finance Execution Capabilities
Oppenheimer’s Healthcare Investment Banking Group Closes Four Life Sciences M&A Transactions in 2023 Year-to-Date.
Joint Bookrunner on Veru Inc.'s Follow-On Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Veru Inc.'s $37,950,000 Confidentially Marketed Follow-On Offering
Joint Bookrunner on Tarsus Pharmaceuticals' Follow-On Offering
Oppenheimer & Co. Inc. Acted as Joint Bookrunner on Tarsus Pharmaceuticals’ Follow-On Offering
Joint Bookrunner on Soleno Therapeutics, Inc.'s $69,000,000 Underwritten Public Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Soleno Therapeutics, Inc.’s $69,000,000 underwritten public offering and Placement Agent on its $60,000,000 concurrent private placement
Joint Bookrunner on HCI Group, Inc.'s Follow-On Offering
HCI Group, Inc. (“HCI”) (NYSE: HCI) announced the pricing of its public follow-on offering of 1,150,000 shares of its common stock at a price to the public of $78.00 per share. HCI intends to use the net proceeds from the offering for general corporate purposes, including the continued assumption of policies from Citizens Property Insurance Corporation.
Joint Bookrunner on Biomea Fusion, Inc.'s Follow-On Offering
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $30.00 per share.
FDA and IRA Insights (1H'23)
Oppenheimer’s latest FDA and IRA insights is now available upon request.